Partner
Deals & Disputes
Gide advises the underwriters on the USD 113.3 million IPO of Nanobiotix on the Nasdaq Global Market
Nanobiotix is a late-stage French developer of nanoparticle drugs that improve cancer radiotherapy. Established in 2003, the company has been listed on Euronext since 2012.
Gide advised the underwriters on French law aspects, with a team headed by partner Arnaud Duhamel and counsel Guilhem Richard, working with associates Juliette Pierre and Mélanie Simon. The tax aspects were handled by counsel Alexandre Bochu. The underwriters were advised by Cooley LLP on US law aspects.
Nanobiotix was represented by Jones Day on aspects of US and French law.
